CLAL BIOTECHNOLOGY INDUSTRIES LTD. Inactive Instrument
Clal Biotechnology Industries Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
CBI
IL0011042806
Investment Holding Companies
| Sales 2022 | 370K 97.19K | Sales 2023 | 104K 27.32K | Capitalization | 62.27M 16.36M |
|---|---|---|---|---|---|
| Net income 2022 | -61M -16.02M | Net income 2023 | -31M -8.14M | EV / Sales 2022 | 331 x |
| Net Debt 2022 | 23.85M 6.26M | Net Debt 2023 | 22.4M 5.88M | EV / Sales 2023 | 814 x |
| P/E ratio 2022 |
-1.6
x | P/E ratio 2023 |
-2.01
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.65% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Assaf Segal
CEO | Chief Executive Officer | 51 | 15-06-30 |
Liat Nissan
DFI | Director of Finance/CFO | 46 | - |
Arnon Aharon
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 03-05-08 | |
Yuval Yanai
BRD | Director/Board Member | 71 | 15-11-17 |
Gad Keren
BRD | Director/Board Member | 73 | 20-02-16 |
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| +16.03% | 74.61B | |
| +52.68% | 16.66B | |
| +3.66% | 15.56B | |
| +6.84% | 13.66B | |
| -1.13% | 12.18B | |
| +9.84% | 12.06B | |
| +6.24% | 10.96B | |
| +31.64% | 9.95B | |
| -1.71% | 9.59B |
